Table 2.
Immune function parameters in peripheral blood leukocytes and inflammation parameters in monocyte cultures at basal conditions and in the plasma of participants in the placebo and supplement groups before and after the treatment.
| Placebo | Supplement | |||
|---|---|---|---|---|
| Initial | Post-Treatment | Initial | Post-Treatment | |
| Immune Function Parameters | ||||
| Phagocytic efficacy | 65 ± 6 | 69 ± 7 | 62 ± 10 | 75 ± 15 ** |
| Natural Killer activity (% Lysis of tumoral cells) | 51.8 ± 26.2 | 50.5 ± 22.1 | 58.8 ± 26 | 52.4 ± 23.1 |
| Proliferative response to LPS (c.p.m) | 4637 ± 2651 | 4952 ± 1783 | 4973 ± 2556 | 6594 ± 2199 * |
| Inflammation Parameters in Plasma | ||||
| IL-6 concentration (pg/mL) | 2.6 ± 2.2 | 3.7 ± 2.8 | 4.8 ± 3.8 | 10.4 ± 6.7 *** |
| IL-2 concentration (pg/mL) | 2.4 ± 2 | 1.9 ± 1.4 | 2.3 ± 1.3 | 0.9 ± 0.6 ** |
| Inflammation Parameters in Monocyte Cultures | ||||
| Basal proliferative response (c.p.m) | 607 ± 243 | 577 ± 232 | 686 ± 131 | 580 ± 216 * |
| TNFα concentration (pg/mL) | 340 ± 183 | 494 ± 143 | 350 ± 177 | 386 ± 132 |
| IL-1β concentration (pg/mL) | 759 ± 571 | 994 ± 180 | 749 ± 593 | 573 ± 202 *** |
| IL-6 concentration (pg/mL) | 1109 ± 337 | 1283 ± 266 | 930 ± 418 | 1311 ± 251 *** |
| TNFα/IL-10 ratio (pg/mL) | 0.68 ± 0.62 | 0.53 ± 0.46 | 0.64 ± 0.54 | 0.32 ± 0.26 ** |
Values are presented as the mean ± standard deviation. * p < 0.05, ** p < 0.01, and *** p < 0.001, indicating statistical significance compared to the initial condition. LPS: lipopolysaccharide.